Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

1(25%)

Results Posted

200%(2 trials)

Terminated

2(50%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Terminated(2)

Detailed Status

Terminated2

Active, not recruiting1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

active_not_recruiting125%

terminated250%

completed125%

Recent Activity

1 active trials

Showing 4 of 4

active_not_recruitingphase_1

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

NCT04279847

terminatedphase_1

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137

terminatedphase_1

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

NCT02959437

completedphase_1

A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants

NCT06941077

Clinical Trials (4)

Showing 4 of 4 trials

NCT04279847Phase 1

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Active Not Recruiting

NCT02711137Phase 1

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Terminated

NCT02959437Phase 1

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

Terminated

NCT06941077Phase 1

A Study to Evaluate the Relative Bioavailability of New Formulations of INCB057643 Tablets Administered Orally in Healthy Participants

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4